Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
DDX58, also known as RIG-I, is a cytoplasmic pattern recognition receptor that plays a central role in the innate immune response. It recognizes viral double-stranded RNA with 5' triphosphate ends, activating downstream signaling cascades leading to the production of type I interferons and proinflammatory cytokines. RIG-I is crucial for antiviral defense and is involved in the regulation of inflammation, autophagy, apoptosis, and tumor immune responses. Mutations can lead to excessive interferon pathway activation, and variants are associated with susceptibility to severe influenza infection and autoimmune diseases. High expression levels correlate with prognosis across multiple cancers.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on DEAD-box helicase 58 (RIG-I).